Vident Investment Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-58,348
| Closed | -$3.73M | – | 144 |
|
|
2023
Q2 | $3.73M | Sell |
58,348
-80,803
| -58% | -$5.42M | 0.13% | 182 |
|
|
2023
Q1 | $9.64M | Buy |
139,151
+48,888
| +54% | +$3.45M | 0.31% | 81 |
|
|
2022
Q4 | $6.49M | Buy |
90,263
+17,089
| +23% | +$1.29M | 0.24% | 129 |
|
|
2022
Q3 | $4.47M | Sell |
73,174
-12,368
| -14% | -$897K | 0.15% | 180 |
|
|
2022
Q2 | $6.59M | Sell |
85,542
-8,066
| -9% | -$614K | 0.2% | 125 |
|
|
2022
Q1 | $6.84M | Buy |
93,608
+3,831
| +4% | +$257K | 0.18% | 132 |
|
|
2021
Q4 | $5.6M | Sell |
89,777
-4,633
| -5% | -$272K | 0.15% | 162 |
|
|
2021
Q3 | $5.58M | Buy |
94,410
+22,887
| +32% | +$1.51M | 0.17% | 122 |
|
|
2021
Q2 | $4.78M | Buy |
71,523
+3,122
| +5% | +$204K | 0.15% | 135 |
|
|
2021
Q1 | $4.32M | Buy |
68,401
+6,650
| +11% | +$414K | 0.15% | 124 |
|
|
2020
Q4 | $3.83M | Buy |
61,751
+7,159
| +13% | +$440K | 0.16% | 110 |
|
|
2020
Q3 | $3.29M | Sell |
54,592
-32,858
| -38% | -$1.98M | 0.16% | 112 |
|
|
2020
Q2 | $5.14M | Sell |
87,450
-2,115
| -2% | -$127K | 0.27% | 75 |
|
|
2020
Q1 | $4.99M | Sell |
89,565
-11,296
| -11% | -$690K | 0.33% | 68 |
|
|
2019
Q4 | $6.47M | Buy |
100,861
+52,811
| +110% | +$3.02M | 0.4% | 44 |
|
|
2019
Q3 | $2.44M | Sell |
48,050
-2,172
| -4% | -$102K | 0.21% | 78 |
|
|
2019
Q2 | $2.28M | Sell |
50,222
-966
| -2% | -$45K | 0.18% | 81 |
|
|
2019
Q1 | $2.44M | Sell |
51,188
-10,503
| -17% | -$523K | 0.13% | 228 |
|
|
2018
Q4 | $3.21M | Sell |
61,691
-8,181
| -12% | -$440K | 0.18% | 112 |
|
|
2018
Q3 | $4.34M | Sell |
69,872
-2,459
| -3% | -$146K | 0.17% | 96 |
|
|
2018
Q2 | $4M | Buy |
72,331
+19,157
| +36% | +$1.03M | 0.16% | 118 |
|
|
2018
Q1 | $2.86M | Buy |
53,174
+6,180
| +13% | +$398K | 0.12% | 254 |
|
|
2017
Q4 | $2.88M | Sell |
46,994
-2,485
| -5% | -$155K | 0.13% | 219 |
|
|
2017
Q3 | $3.15M | Buy |
49,479
+28,482
| +136% | +$1.66M | 0.17% | 125 |
|
|
2017
Q2 | $1.17M | Buy |
20,997
+5,805
| +38% | +$316K | 0.1% | 306 |
|
|
2017
Q1 | $826K | Buy |
15,192
+2,532
| +20% | +$139K | 0.08% | 324 |
|
|
2016
Q4 | $740K | Buy |
12,660
+2,823
| +29% | +$154K | 0.09% | 306 |
|
|
2016
Q3 | $530K | Sell |
9,837
-89
| -0.9% | -$5.72K | 0.07% | 335 |
|
|
2016
Q2 | $730K | Sell |
9,926
-44,306
| -82% | -$3.13M | 0.1% | 309 |
|
|
2016
Q1 | $3.46K | Buy |
54,232
+22,952
| +73% | +$1.45M | 0.21% | 243 |
|
|
2015
Q4 | $2.15M | Buy |
31,280
+31,135
| +21,472% | +$2.06M | 0.27% | 122 |
|
|
2015
Q3 | $9K | Sell |
145
-39,505
| -100% | -$2.51M | ﹤0.01% | 788 |
|
|
2015
Q2 | $2.64M | Buy |
39,650
+28,734
| +263% | +$1.89M | 0.35% | 46 |
|
|
2015
Q1 | $704K | Sell |
10,916
-7,238
| -40% | -$453K | 0.14% | 202 |
|
|
2014
Q4 | $1.07M | Buy |
+18,154
| New | +$1.02M | 0.36% | 36 |
|
Other funds holding BMY
Vident Investment Advisory's BMY Position: Q3 2023 in Review
Vident Investment Advisory sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 58,348 shares — an estimated $3.73M sold.
Vident Investment Advisory first reported a position in BMY in Q4 2014 and held it in 35 quarters. The position peaked at $9.64M in Q1 2023. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.
- Vident Investment Advisory reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
- Vident Investment Advisory sold 58,348 Bristol-Myers Squibb shares in Q3 2023, an estimated $3.73M.
- Vident Investment Advisory first reported a position in Bristol-Myers Squibb in Q4 2014 and held it in 35 quarters.
- Vident Investment Advisory's Bristol-Myers Squibb position peaked at $9.64M in Q1 2023.
- 2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.
Based on Vident Investment Advisory's 13F filing for Q3 2023.